Insulet | PODD - Selling And Administration Expenses


Insulet reported $317.2M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Abbott USD 3.6B 330M Jun/2026
Align Technology USD 462.67M 2.67M Jun/2026
AtriCure USD 82.56M 1.99M Jun/2026
Baxter International USD 735M 7M Jun/2026
Becton, Dickinson and Co. USD 1.21B 180M Mar/2026
Boston Scientific USD 1.8B 22M Jun/2026
Cardinal Health USD 1.51B 6M Mar/2026
Cooper Companies USD 676.2M 303.1M Mar/2026
Dexcom USD 358.7M 9M Jun/2026
Edwards Lifesciences USD 561.2M 39M Jun/2026
Eli Lilly USD 2.93B 198M Mar/2026
Globus Medical USD 297.77M 20.7M Mar/2026
ICU Medical USD 155.81M 3.04M Dec/2025
Inogen USD 43.77M 510K Jun/2024
Insulet USD 317.2M 14.2M Mar/2026
Integra LifeSciences USD 166.22M 12.01M Jun/2026
J&J USD 6.42B 381M Jun/2026
Medtronic 2.96B 9M Dec/2025
Merit Medical Systems USD 129.23M 18.76M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Solventum Corp USD 783M 24M Mar/2026
Stryker USD 2.12B 32M Jun/2026
Tandem Diabetes Care USD 99.86M 5.34M Dec/2025
Teleflex USD 226.01M 3.64M Mar/2026
West Pharmaceutical Services USD 117.6M 18.1M Jun/2026
Zimmer Biomet Holdings USD 849.9M 5.8M Mar/2026